
Gyan Chandra
Examiner (ID: 12063, Phone: (571)272-2922 , Office: P/1646 )
| Most Active Art Unit | 1646 |
| Art Unit(s) | 1646, 1674 |
| Total Applications | 1424 |
| Issued Applications | 820 |
| Pending Applications | 137 |
| Abandoned Applications | 480 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19157747
[patent_doc_number] => 20240150454
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS
[patent_app_type] => utility
[patent_app_number] => 18/499523
[patent_app_country] => US
[patent_app_date] => 2023-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56309
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18499523
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/499523 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | Oct 31, 2023 | Pending |
Array
(
[id] => 19034150
[patent_doc_number] => 20240083965
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => PRODRUGS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/384511
[patent_app_country] => US
[patent_app_date] => 2023-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20610
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 203
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18384511
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/384511 | PRODRUGS AND USES THEREOF | Oct 26, 2023 | Pending |
Array
(
[id] => 19081893
[patent_doc_number] => 20240108694
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-04
[patent_title] => METHOD OF DELIVERING A SOMATOSTATIN COMPOUND INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
[patent_app_type] => utility
[patent_app_number] => 18/481875
[patent_app_country] => US
[patent_app_date] => 2023-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23389
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481875
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/481875 | METHOD OF DELIVERING A SOMATOSTATIN COMPOUND INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | Oct 4, 2023 | Abandoned |
Array
(
[id] => 19300072
[patent_doc_number] => 20240228641
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2024-07-11
[patent_title] => ANTIBODIES BINDING TO CD30 AND CD3
[patent_app_type] => utility
[patent_app_number] => 18/478711
[patent_app_country] => US
[patent_app_date] => 2023-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31194
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18478711
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/478711 | ANTIBODIES BINDING TO CD30 AND CD3 | Sep 28, 2023 | Pending |
Array
(
[id] => 19300072
[patent_doc_number] => 20240228641
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2024-07-11
[patent_title] => ANTIBODIES BINDING TO CD30 AND CD3
[patent_app_type] => utility
[patent_app_number] => 18/478711
[patent_app_country] => US
[patent_app_date] => 2023-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31194
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18478711
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/478711 | ANTIBODIES BINDING TO CD30 AND CD3 | Sep 27, 2023 | Pending |
Array
(
[id] => 18923410
[patent_doc_number] => 20240026414
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => Compositions and Methods for Peptide Production
[patent_app_type] => utility
[patent_app_number] => 18/477276
[patent_app_country] => US
[patent_app_date] => 2023-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18290
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18477276
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/477276 | Compositions and methods for peptide production | Sep 27, 2023 | Issued |
Array
(
[id] => 19097772
[patent_doc_number] => 20240117000
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/459394
[patent_app_country] => US
[patent_app_date] => 2023-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30937
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459394
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/459394 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Aug 30, 2023 | Pending |
Array
(
[id] => 19083174
[patent_doc_number] => 20240109975
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-04
[patent_title] => BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/449876
[patent_app_country] => US
[patent_app_date] => 2023-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22123
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18449876
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/449876 | BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS | Aug 14, 2023 | Abandoned |
Array
(
[id] => 19156136
[patent_doc_number] => 20240148843
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => Peptide
[patent_app_type] => utility
[patent_app_number] => 18/448678
[patent_app_country] => US
[patent_app_date] => 2023-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6782
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448678
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/448678 | Peptide | Aug 10, 2023 | Pending |
Array
(
[id] => 18784648
[patent_doc_number] => 20230372237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-23
[patent_title] => THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
[patent_app_type] => utility
[patent_app_number] => 18/230086
[patent_app_country] => US
[patent_app_date] => 2023-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27260
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18230086
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/230086 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | Aug 2, 2023 | Pending |
Array
(
[id] => 19127271
[patent_doc_number] => 20240132624
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => POLYPEPTIDES BINDING TO A SPECIFIC EPITOPE OF THE NEONATAL FC RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 18/360393
[patent_app_country] => US
[patent_app_date] => 2023-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54504
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18360393
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/360393 | POLYPEPTIDES BINDING TO A SPECIFIC EPITOPE OF THE NEONATAL FC RECEPTOR | Jul 26, 2023 | Pending |
Array
(
[id] => 18901413
[patent_doc_number] => 20240016898
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
[patent_app_type] => utility
[patent_app_number] => 18/357666
[patent_app_country] => US
[patent_app_date] => 2023-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11155
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18357666
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/357666 | Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes | Jul 23, 2023 | Issued |
Array
(
[id] => 20715566
[patent_doc_number] => 12630803
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-05-19
[patent_title] => Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
[patent_app_type] => utility
[patent_app_number] => 18/354452
[patent_app_country] => US
[patent_app_date] => 2023-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 25
[patent_no_of_words] => 11252
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18354452
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/354452 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | Jul 17, 2023 | Issued |
Array
(
[id] => 18921501
[patent_doc_number] => 20240024505
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => SYNTHETIC CELLULAR SIGNALING PATHWAYS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/221206
[patent_app_country] => US
[patent_app_date] => 2023-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50084
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18221206
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/221206 | Synthetic cellular signaling pathways and uses thereof | Jul 11, 2023 | Issued |
Array
(
[id] => 19081930
[patent_doc_number] => 20240108731
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-04
[patent_title] => THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22
[patent_app_type] => utility
[patent_app_number] => 18/345832
[patent_app_country] => US
[patent_app_date] => 2023-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20125
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18345832
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/345832 | Therapeutic derivatives of interleukin-22 | Jun 29, 2023 | Issued |
Array
(
[id] => 18806987
[patent_doc_number] => 20230381320
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22
[patent_app_type] => utility
[patent_app_number] => 18/345775
[patent_app_country] => US
[patent_app_date] => 2023-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19973
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18345775
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/345775 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | Jun 29, 2023 | Pending |
Array
(
[id] => 18709190
[patent_doc_number] => 20230331802
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => METHOD TO PREPARE THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/344130
[patent_app_country] => US
[patent_app_date] => 2023-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18344130
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/344130 | METHOD TO PREPARE THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS | Jun 28, 2023 | Pending |
Array
(
[id] => 19265373
[patent_doc_number] => 20240209072
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => Method of Reducing Blood Glucose Levels and Inhibiting Secreted aP2
[patent_app_type] => utility
[patent_app_number] => 18/341404
[patent_app_country] => US
[patent_app_date] => 2023-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9452
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18341404
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/341404 | Method of reducing glucose intolerance or insulin resistance in a patient in need thereof | Jun 25, 2023 | Issued |
Array
(
[id] => 19310490
[patent_doc_number] => 12036284
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-16
[patent_title] => Compositions and methods of treatment for severe hypertriglyceridemia
[patent_app_type] => utility
[patent_app_number] => 18/340421
[patent_app_country] => US
[patent_app_date] => 2023-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 46
[patent_no_of_words] => 32164
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 196
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18340421
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/340421 | Compositions and methods of treatment for severe hypertriglyceridemia | Jun 22, 2023 | Issued |
Array
(
[id] => 18724349
[patent_doc_number] => 20230338491
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => METHOD FOR SCREENING INDIVIDUAL TUMOR NEOANTIGEN PEPTIDE, AND VACCINE FORMULATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/338605
[patent_app_country] => US
[patent_app_date] => 2023-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8156
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 665
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18338605
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/338605 | METHOD FOR SCREENING INDIVIDUAL TUMOR NEOANTIGEN PEPTIDE, AND VACCINE FORMULATION THEREOF | Jun 20, 2023 | Pending |